Ongoing deliveries of COVID-19 Vaccine AstraZeneca to Malaysia from Thailand will be complemented with doses from other AstraZeneca supply chains, which could include those in Korea and Europe, ensuring accelerated supply before year-end.
The accelerated year-end supply is in response to the Delta outbreak and part of AstraZeneca’s commitment to deliver a total of 6.4 million doses directly to Malaysia, in addition to the millions more supplied via COVAX and donations from other countries.
Dr. Sanjeev Panchal, Country President of AstraZeneca Malaysia, said: “The support of additional global supply chains reflects AstraZeneca’s commitment to leave no stone unturned in delivery to Malaysia and the region in the fastest possible timeframe. We remain committed to ensuring a sustainable supply of vaccine doses, with a highly vaccinated population necessary for our safe reopening and transition towards an endemic COVID-19.”
All of AstraZeneca’s vaccination manufacturing hubs in the region continue to produce doses at their full production capacity.
COVID-19 Vaccine AstraZeneca
The COVID-19 Vaccine AstraZeneca, (ChAdOx1-S [Recombinant]), formerly AZD1222, was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
For further details please contact email@example.com.